FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

FOLFOX* followed by FOLFIRI** or reverse sequence treatment regimen have been used as a standard treatment modality in metastatic colorectal cancer.Oxaliplatin and Irinotecan were used for advanced gastric cancer also. The investigators study was designed to evaluate the safety and efficacy of FOLFOX followed by FOLFIRI or reverse sequence treatment regimen as a first-line and second line therapy for patients with relapsed or metastatic gastric cancer similar with colorectal cancer.

*FOLFOX: oxaliplatin followed by leucovorin before bolus 5-FU followed by continuous infusion 5-FU

**FOLFIRI: irinotecan followed by leucovorin before bolus 5-FU followed by continuous infusion 5-FU

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A University Hospital
• Collaborator: Pusan National University Yangsan Hospital
• Treatments: Camptothecin; Fluorouracil; Irinotecan; Oxaliplatin

Criteria

Inclusion Criteria:

• Histologically confirmed gastric cancer

• No prior chemotherapy for palliative setting

• ECOG PS <3

• Measurable lesion on CT

• adequate kidney function (CCr ≥ 40 ml/min)

• adequate liver function (Transaminase < 3 X upper normal value, Bilirubin < 2 mg%)

• adequate BM function (ANC > 1500/ul, platelet > 75000/ul)

• informed consent

Exclusion Criteria:

• other cancer history

• pregnant or breast feeding

• inadequate general condition for chemotherapy

• allergy to oxaliplatin or irinotecan